Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
Maryia ZhdanavaAmanda TeepleDominic PilonAditi ShahGabrielle Caron-LapointeKruti JoshiPublished in: Journal of medical economics (2023)
Nearly half of patients experience access issues with first esketamine nasal spray treatment session. All-cause HRU and healthcare costs trend lower in the 6 months after relative to 6 months before esketamine initiation.
Keyphrases
- major depressive disorder
- healthcare
- bipolar disorder
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- combination therapy
- liver failure
- adipose tissue
- health insurance
- type diabetes
- drug induced
- extracorporeal membrane oxygenation
- chronic rhinosinusitis
- acute respiratory distress syndrome
- respiratory failure